CD274 and melanoma: Herbst et al. reported that responses were seen in patients with tumors of multiple types including melanoma, renal cell carcinoma, and NSCLC expressing high levels of PD-L1, particularly when PD-L1 was expressed by tumor-infiltrating immune cells.